Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. Several
important scientific discoveries in the molecular biology of CRC have changed clinical …

Background The incorporation of novel biomarkers into therapy selection for patients with
metastatic colorectal cancer (mcrc) has significantly improved outcomes. Optimal treatment …

The medical treatment of metastatic colorectal cancer (mCRC) has advanced significantly
over the last 10 years as the result of the introduction of several active cytotoxic and biologic …

Metastatic colorectal cancer (mCRC) is still one of the tumor types with the highest incidence
and mortality. In 2012, colorectal cancer was the second most prevalence cancer among …

Introduction: Since late 1990's therapy of metastatic colorectal cancer (mCRC) patients has
changed considerable, and the combination of doublet or triplet chemotherapy and a …

Treatment strategies for metastatic colorectal cancer (mCRC) patients have undergone
dramatic changes in the past decade and despite improved patient outcomes, there still exist …

Metastatic colorectal cancer is a prevalent disease for which novel targeted therapies and
biologically based combinations are under development. Cytotoxic chemotherapy doublets …

Colorectal cancer (CRC) is a heterogeneous disease entity in terms of both molecular
carcinogenesis and morphologic carcinogenesis multistep pathways. Considerable …

The article summarizes the expert discussion and recommendations on the use of molecular
markers and of biological targeted therapies in metastatic colorectal cancer (mCRC), as well …

In metastatic colorectal cancer (mCRC), an improved understanding of the underlying
pathology and molecular biology has successfully merged with advances in diagnostic …